Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.44 |
| ▸ | ABL2 | P42684 | 6/20 | 0.44 |
| ▸ | CDK8 | P49336 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.43 |
| ▸ | BCR | P11274 | 2/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19316707 | 0.88 | ABL1 (0.58) | ABL1ABL2CDK8CDK1CDK2 | |
| SCHEMBL29614814 | 0.86 | ABL1 (0.49) | ABL1ABL2CDK8CDK1CDK2 | |
| SCHEMBL19307233 | 0.86 | ABL1 (0.49) | ABL1ABL2CDK8CDK1CDK2 | |
| SCHEMBL19317712 | 0.85 | ABL1 (0.57) | ABL1ABL2CDK8CDK1CDK2 | |
| SCHEMBL20214661 | 0.84 | ABL1 (0.46) | ABL1ABL2CDK8CDK1CDK2 | |
| SCHEMBL20214778 | 0.83 | ABL1 (0.52) | ABL1ABL2CDK8MKNK2FGFR4 | |
| SCHEMBL20227782 | 0.81 | ABL1 (0.47) | ABL1ABL2CDK8MKNK2BCR | |
| SCHEMBL20227767 | 0.80 | ABL1 (0.46) | ABL1ABL2CDK8CDK1CDK2 | |
| SCHEMBL19316716 | 0.79 | ABL1 (0.57) | ABL1ABL2CDK8CDK1CDK2 | |
| SCHEMBL19316718 | 0.79 | ABL1 (0.45) | ABL1ABL2CDK8CDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | ABL1 3753/4885ABL2 4577/4885CDK8 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.